INTRODUCTION
Lysosomal glycogen is normally degraded by lysosomal aglucosidase (acid maltase; EC 3.2.1.3), and accumulates when this enzyme is deficient (Hers, 1963) . The disease, known as glycogenosis type II or glycogen-storage disease type II (GSDII), is inherited as an autosomal recessive trait. The clinical manifestations can vary considerably with respect to time of onset and severity of symptoms (McKusick, 1990) .
Apart from clinical heterogeneity, there is also a high degree of biochemical and molecular heterogeneity. A multitude of mutant alleles has been suspected from the molecular abnormalities of the lysosomal a-glucosidase species in cultured fibroblasts and muscle cells from several patients (Reuser et al., 1978 (Reuser et al., , 1987 Beratis et al., 1978 Beratis et al., , 1983 Reuser and Kroos, 1982 ; Van der Ploeg et al., 1989; Hoefsloot et al., 1990a) . Genetic heterogeneity has been demonstrated more directly by Southernand Northern-blot analysis (Martiniuk et al., 1986 (Martiniuk et al., , 1990a Hoefsloot et al., 1988; Reuser et al., 1988) .
The first two reports on mutation analysis in GSDII have appeared recently (Her-mans et al., 199 la; Zhong et al., 1991) . In both cases it concerned a patient with a severe infantile form of the disease. We discovered in two sibs from a consanguineous couple a glutamic acid to lysine substitution at position 521 in the homozygous form. The mutation was confirmed to be responsible for the increased electrophoretic mobility of the mutant enzyme precursor, the deficient proteolytic processing and catalytic activity, and the defective intracellular transport to analyse the effect on biosynthesis, transport and phosphorylation of lysosomal a-glucosidase. Ile substitution appeared to have no significant effect in contrast with results [Martiniuk, Mehler, Bodkin, Tzall, Hirshhorn, Zhong and Hirschhorn (1991) DNA Cell Biol. 10, [681] [682] [683] [684] [685] [686] [687] and was therefore defined as a polymorphism. The Thr-927 -+ Ile substitution deleting one of the seven glycosylation sites was found to be responsible for the decrease in molecular-mass, but not for the deficient proteolytic processing and phosphorylation. It did not cause the enzyme deficiency either. The third mutation leading to the Asp-645 -+ Glu substitution was proven to account in full for the observed defects in transport, phosphorylation and proteolytic processing of the newly synthesized a-glucosidase precursor of the patient. (Hermans et al., 199 la) . Substitution of threonine for methionine at amino acid position 318 was found by Zhong et al. (1991) in one of the two lysosomal a-glucosidase alleles of their patient. The mutation gives major changes in the predicted secondary structure and creates a potential N-linked glycosylation site, but it remains to be investigated whether the new site is actually used. The second allele of the patient was not expressed.
In this study we report on a case of adult GSDII, which was deliberately chosen for its interesting complexity. Fibroblasts from this American black patient (cell line GM1935) were originally investigated by Beratis et al. (1983) . The residual activity of lysosomal a-glucosidase was found to be unusually low compared with the relatively mild clinical phenotype of the patient. When we studied the biosynthesis of lysosomal aglucosidase in cell line GM1935, two molecular abnormalities were observed (Reuser et al., , 1987 . First, the 110 kDa lysosomal a-glucosidase precursor was not processed to mature enzyme. Second, phosphorylation of the precursor was deficient. The latter abnormality prevents formation of the mannose 6-phosphate recognition marker which is assumed to be essential for lysosomal targeting (Creek and Sly, 1984) . Indeed, the amount of enzyme in the lysosomes was found to be extremely low.
In an attempt to explain these findings we have now analysed the genetic phenotype of the patient. Different mutations were detected in the two lysosomal ax-glucosidase alleles. One mutant allele with a premature stop codon was found to be silent. The second allele appeared to harbour two polymorphisms in addition Abbreviations used: GSDII, glycogen-storage disease type 11; 4-MU, 4-methylumbelliferyl a-D-glucopyranoside; 1 x SSC, 0.15 M NaCI/0.015 M sodium citrate; 1 x SSPE, 15 mM NaCI/10 mM NaH2PO4/1 mM EDTA.
to the mutation causing the abnormal properties of the patient's lysosomal a-glucosidase.
The same patient was studied independently by Martiniuk et al. (1991) Reuser et al. (1985) . Cells were pulse-labelled for 2 or 6 h and harvested either directly or after a subsequent chase of 9 h. In some experiments, tunicamycin (final concentration 10 ,ug/ml) was added 1 h before labelling and during labelling to inhibit glycosylation of newly synthesized proteins. Lysosomal a-glucosidase was immunoprecipitated from cell extracts and analysed by SDS/PAGE as described (Hasilik and Neufeld, 1980; Reuser et al., 1985) .
DNA amplification and sequencing DNA and RNA were extracted from cultured fibroblasts by standard procedures (Sambrook et al., 1989) . cDNA synthesis was carried out using Amersham's cDNA Synthesis System Plus and oligo(dT) primers. PCR amplification using intronic or exonic primers specific for lysosomal a-glucosidase was as described (Hermans et al., 1991a) . Each 100,ul of PCR reaction mixture contained approx. 0.5 ,tg of DNA, 100 pmol of each primer and 2 units of Taq polymerase (BRL) in the standard PCR buffer recommended by Sambrook et al. (1989) . Amplification was performed in a Perkin-Elmer Cetus DNA amplifier. The first cycle was: 5 min denaturation at 94 'C, 5 min annealing at 59 'C and 5 min DNA synthesis at 72 'C. Subsequent cycles (25-30) consisted of 2 min at 94 'C, 2 min at 59 'C and 5 min at 72 'C. The DNA-synthesis step of the final cycle was extended to 15 min. In some instances, PCR-amplified DNA fragments were cloned in a T-tailed Bluescript plasmid vector. This so-called T-vector was constructed as described by Marchuk et al. (1991) . DNA fragments were sequenced using the T7 polymerase sequencing kit (Pharmacia LKB Biotechnology Inc.) with appropriate primers.
Slot-blot analysis and alIele-specffic oligonucleotide hybridization PCR products were denatured in 0.4 M NaOH/25 mM EDTA for 10 min and applied directly to Hybond N+ membranes using a slot-blot apparatus. The filters were air-dried, prehybridized for 1 h at 42 'C in 5 x SSPE/1 0% SDS/50 jug/ml salmon sperm DNA, and subsequently hybridized for 3 h in the same solution to 32P-labelled oligonucleotides. The filters were washed in 6 x SSC for 5 min at 2-3 'C below the estimated melting temperature (Wallace et al., 1981) .
Site-directed mutagenesis Site-directed mutagenesis was carried out as described by Hermans et al. (1991b 
Transient expression in COS cells
Wild-type and mutant cDNAs were cloned in the eukaryotic expression plasmid pSG5. The transfection of COS cells was carried out as described by Hoefsloot et al. (1990b) . The activity of lysosomal ac-glucosidase in the cell homogenates and the culture media was measured with 4-methylumbelliferyl a-Dglucopyranoside (4-MU) and with glycogen as described by Hermans et al. (199lb) . Radioactive labelling and analysis of lysosomal a-glucosidase expressed in COS cells was as mentioned above.
Immunocytochemistry on transiently transfected COS cells was performed exactly as described before (Hoefsloot et al., 1990b) .
RESULTS AND DISCUSSION Delineation of the molecular phenotype
The lysosomal a-glucosidase activity in the fibroblast cell line GM1935 derived from a black American adult with GSDII is 1-3 00 of the average control value (Beratis et al., 1983; Reuser et al., 1985 Reuser et al., , 1987 . Figure l(a) reveals the molecular nature of the enzyme deficiency. In control fibroblasts, the enzyme is synthesized as a precursor of approximately 110 kDa, and is proteolytically processed to a long-lived 95 kDa intermediate. In a later stage, mature enzyme of 76 and 70 kDa is formed (Hasilik and Neufeld, 1980; Oude Elferink et al., 1985; Reuser et al., 1985) . These major molecular forms of lysosomal a-glucosidase It is therefore an intrinsic feature of the mutant lysosomal a-glucosidase precursor. These results confirm our earlier findings except that the decrease in molecular mass of the mutant precursor escaped our attention in the high-percentage polyacrylamide gels used previously .
A decrease in the apparent molecular mass of a polypeptide can have several causes. It can result from a deletion, an aberrant splicing of the transcript or a point mutation introducing a premature stop codon. Also a mutation causing the loss of a glycosylation site has to be considered. We have demonstrated recently that even a single amino acid substitution can give rise to a significant difference in the electrophoretic mobility of lysosomal ca-glucosidase on SDS/PAGE (Hermans et al., 1991a,b) . The possible lack of a glycosylation site was assessed by comparing the size of the unglycosylated and glycosylated wild-type and mutant precursors. To this end, glycosylation was inhibited with tunicamycin. Figure 2 illustrates that the wild-type and mutant lysosomal a-glucosidase precursors are the same size (97 kDa) when synthesized in the presence of tunicamycin. On the basis of these results our working hypothesis was that the lysosomal a-glucosidase precursor of mutant GM 1935 lacks one of the seven glycosylation sites. In the preceding paper (Hermans et al., 1993) , we have demonstrated by site-directed mutagenesis that individual elimination of six of these seven sites does not lead to defective processing and loss of enzyme function. Only the loss of the glycosylation site at amino acid position 233 was found to interfere with enzyme maturation and transport, but the phosphorylation was not affected. Therefore we conclude that the lack of a glycosylation site alone cannot account for the abnormalities observed in cell line GM1935. 
Sequence analysis
To identify the mutations responsible for the molecular phenotype of GM1935, we PCR-amplified all exonic regions of the lysosomal a-glucosidase gene. Most PCR products were sequenced directly. In some instances, however, it was necessary to clone the PCR fragments before sequencing. In these cases at least four clones were analysed. Sequence analysis of the complete coding region revealed several differences from the wild-type cDNA sequence Martiniuk et al., 1990b) Martiniuk et al. (1991) which were obtained with a different methodology.
The question remains of which of the mutations is responsible for the defect in post-translational modification. The Thr-927 -. Ile mutation eliminating the glycosylation site at Asn-925 seems unlikely, since we have demonstrated that the loss of this site does not interfere with enzyme processing or function (Hermans et al., 1993) . Moreover, the Chou-Fasman and the Gamier algorithms did not predict a significant change in the secondary structure of the protein (Chou and Fasman, 1978; Gamier et al., 1978) . No (Figure 4 , pulse).
Within 9 h of the chase, the wild-type precursor was converted into the 95 kDa intermediate and the 76 kDa mature form of lysosomal a-glucosidase (Figure 4, chase 9 h (Hermans et al., 1993) .
The proteolytic processing of the precursor containing the Asp-645 -+ Glu substitution was delayed as was the processing of the double mutant precursor. (The respective 1 10 kDa and 108 kDa precursor species were still visible after 9 h of chase.)
A comparable picture was obtained after 30 h of chase, except that the Glu-545 and double mutant precursor were no longer detectable (Figure 4 , chase 30 h). The mutant species are apparently degraded since they are not converted into mature enzyme and not secreted either (Figure 4, secretion) .
The biosynthesis of lysosomal a-glucosidase containing the Arg-854 -. Stop mutation is illustrated in Figure 5 (leucine incorporation Summarizing the results presented in Table 2 and Figures 4-6, we conclude that it is the double mutant that mimics the molecular defect in cell line GM 1936, but the deleterious effect on enzyme biosynthesis and function is caused by the Glu rather than the Thr-927 -4 Ile substitution.
Subcellular localization
Immunocytochemistry was performed to study the intracellular localization of the mutant proteins in the transiently transfected COS cells. Typical punctate lysosomal labelling was obtained for Ultrathin cryosections were incubated with rabbit polyclonal antiserum against human lysosomal ax-glucosidase and subsequently with goat anti-rabbit IgG coupled to colloidal gold. Mutant protein was found in normal amounts in the endoplasmic reticulum (R) but very little enzyme was detectable in the lysosomes (L). M: mitochondrion. Bar is 0.1 ,um. (a) Lysosome; (b) endoplasmic reticulum. lysosomal a-glucosidase with the Thr-927 Ile substitution (Figure 7a ), but expression of lysosomal a-glucosidase with the single Asp-645 Glu or the double mutation resulted in a labelling pattern characteristic of endoplasmic reticulum. Lysosomal labelling was barely detectable (Figure 7b ). Semiquantitative data on the lysosomal labelling were obtained by immunoelectron microscopy on ultrathin cryosections. To this end, the number of gold particles per lysosome was counted in 31 randomly chosen lysosomes. The results are presented in Ile substitutions were present simultaneously. Both the wild-type and the Thr-927 Ile-substituted lysosomal aglucosidases were not only present in the lysosomes but also in the various compartments ofthe glycoprotein-transport pathway, including the endoplasmic reticulum, the Golgi cisternae and the trans-Golgi network (results not shown). The Asp-645 -4 Glu and the double-mutant a-glucosidase precursors were mainly localized in the endoplasmic reticulum (Figure 8 ). This abnormal enzyme distribution suggests that the mutant precursor is trans-43 + 21 31 +32 13 +16 3+3 ported inefficiently from the endoplasmic reticulum to the Golgi. This is in line with the observed phosphorylation defect. The N-acetylglucosaminyl phosphotransferase responsible for the incorporation of 32P in the lysosomal a-glucosidase precursor is thought to be located in the cis-most Golgi cisternae Gabel, 1988, 1989) . Inefficient transfer of the mutant precursor to this compartment will therefore automatically lead to an apparent phosphorylation defect. On the basis of our present findings, we consider it less likely that the mutation in this patient affects the N-acetylglucosaminyl phosphotransferaserecognition site directly. The dramatic effect of the Asp to Glu substitution at position 645 is possibly caused by the change in secondary structure, as predicted by the Chou-Fasman algorithm. There are several examples in the literature of mutant proteins that do not exit the endoplasmic reticulum because of wrong folding (Pelham, 1989) .
We have no explanation for the apparent discrepancy between our results and those reported by Martiniuk et al. (1991) , where it concerns the effect of the amino acid substitutions. The experimental approach is only different in the sense that Martiniuk et al. (1991) used SV40-immortalized fibroblasts from a patient with GSDII for transient expression of lysosomal a-glucosidase cDNA whereas we used COS-l cells. We have, however, not experienced a difference in the biosynthesis, the post-translational modification and the intracellular location of wild-type and mutant forms of lysosomal a-glucosidase in The most difficult to explain is the clinical phenotype of the patient. The mutation analysis has shown that only one allele is expressed and that this allele does not produce a substantial amount of functional lysosomal a-glucosidase. The results are in this respect no different from those obtained with fibroblasts from the patient. The low level of residual activity is typical for patients with an infantile form of glycogenosis type II. The relatively slow progression of the disease in this black adult patient remains an enigma, unless the biosynthesis of this mutant lysosomal a-glucosidase is different in muscle from that in fibroblasts or transfected COS cells.
